Advertisement

European Journal of Clinical Pharmacology

, Volume 70, Issue 2, pp 215–223 | Cite as

Patient- and physician-related risk factors for hyperkalaemia in potassium-increasing drug–drug interactions

  • Emmanuel EschmannEmail author
  • Patrick E. Beeler
  • Vladimir Kaplan
  • Markus Schneemann
  • Gregor Zünd
  • Jürg Blaser
Pharmacoepidemiology and Prescription

Abstract

Purpose

Hyperkalaemia due to potassium-increasing drug–drug interactions (DDIs) is a clinically important adverse drug event. The purpose of this study was to identify patient- and physician-related risk factors for the development of hyperkalaemia.

Methods

The risk for adult patients hospitalised in the University Hospital Zurich between 1 December 2009 and 31 December 2011 of developing hyperkalaemia was correlated with patient characteristics, number, type and duration of potassium-increasing DDIs and frequency of serum potassium monitoring.

Results

The 76,467 patients included in this study were prescribed 8,413 potentially severe potassium-increasing DDIs. Patient-related characteristics associated with the development of hyperkalaemia were pulmonary allograft [relative risk (RR) 5.1; p < 0.0001), impaired renal function (RR 2.7; p < 0.0001), diabetes mellitus (RR 1.6; p = 0.002) and female gender (RR 1.5; p = 0.007). Risk factors associated with medication were number of concurrently administered potassium-increasing drugs (RR 3.3 per additional drug; p < 0.0001) and longer duration of the DDI (RR 4.9 for duration ≥6 days; p < 0.0001). Physician-related factors associated with the development of hyperkalaemia were undetermined or elevated serum potassium level before treatment initiation (RR 2.2; p < 0.001) and infrequent monitoring of serum potassium during a DDI (interval >48 h: RR 1.6; p < 0.01).

Conclusion

Strategies for reducing the risk of hyperkalaemia during potassium-increasing DDIs should consider both patient- and physician-related risk factors.

Keywords

Drug–drug interactions Hyperkalaemia Monitoring Potassium Risk factors 

Notes

Disclosure of conflict of interests

None.

Supplementary material

228_2013_1597_MOESM1_ESM.pdf (15 kb)
Online Resource 1 (PDF 14.7 kb)
228_2013_1597_MOESM2_ESM.pdf (26 kb)
Online Resource 2 (PDF 26 kb)
228_2013_1597_MOESM3_ESM.pdf (48 kb)
Online Resource 3 (PDF 48 kb)

References

  1. 1.
    Kohn LT CJ, Donaldson MS (eds) (1999) To err is human. Building a safer health system. Committee on Quality in Health Care, Institute of Medicine, Washington D.C.Google Scholar
  2. 2.
    Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM (2008) Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 168(17):1890–1896. doi: 10.1001/archinternmed.2008.3 PubMedGoogle Scholar
  3. 3.
    Hamilton RA, Briceland LL, Andritz MH (1998) Frequency of hospitalization after exposure to known drug–drug interactions in a Medicaid population. Pharmacotherapy 18(5):1112–1120PubMedGoogle Scholar
  4. 4.
    Sanchez Munoz-Torrero JF, Barquilla P, Velasco R, Fernandez Capitan Mdel C, Pacheco N, Vicente L, Chicon JL, Trejo S, Zamorano J, Lorenzo Hernandez A (2010) Adverse drug reactions in internal medicine units and associated risk factors. Eur J Clin Pharmacol 66(12):1257–1264. doi: 10.1007/s00228-010-0866-6 PubMedCrossRefGoogle Scholar
  5. 5.
    Zwart-van Rijkom JE, Uijtendaal EV, ten Berg MJ, van Solinge WW, Egberts AC (2009) Frequency and nature of drug-drug interactions in a Dutch university hospital. Br J Clin Pharmacol 68(2):187–193. doi: 10.1111/j.1365-2125.2009.03443.x PubMedCrossRefGoogle Scholar
  6. 6.
    Gennari FJ (2002) Disorders of potassium homeostasis. Hypokalemia and hyperkalemia. Crit Care Clin 18(2):273–288PubMedCrossRefGoogle Scholar
  7. 7.
    van der Sijs H, Aarts J, Vulto A, Berg M (2006) Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc 13(2):138–147. doi: 10.1197/jamia.M1809 PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Smithburger PL, Buckley MS, Bejian S, Burenheide K, Kane-Gill SL (2011) A critical evaluation of clinical decision support for the detection of drug-drug interactions. Expert Opin Drug Saf 10(6):871–882 doi: 10.1517/14740338.2011.583916 Google Scholar
  9. 9.
    Abarca J, Colon LR, Wang VS, Malone DC, Murphy JE, Armstrong EP (2006) Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm 12(5):383–389PubMedGoogle Scholar
  10. 10.
    Oertle M (2012) Frequency and nature of drug-drug interactions in a Swiss primary and secondary acute care hospital. Swiss Med Wkly 142:w13522. doi: 10.4414/smw.2012.13522 PubMedGoogle Scholar
  11. 11.
    Beeler PE, Eschmann E, Rosen C, Blaser J (2013) Use of an on-demand drug-drug interaction checker by prescribers and consultants: a retrospective analysis in a swiss teaching hospital. Drug Saf 36(6):427–434. doi: 10.1007/s40264-013-0022-1 PubMedCrossRefGoogle Scholar
  12. 12.
    Uijtendaal EV, Zwart-van Rijkom JE, van Solinge WW, Egberts TC (2011) Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs. Eur J Clin Pharmacol 67(9):933–940. doi: 10.1007/s00228-011-1028-1 PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Zopf Y, Rabe C, Neubert A, Janson C, Brune K, Hahn EG, Dormann H (2009) Gender-based differences in drug prescription: relation to adverse drug reactions. Pharmacology 84(6):333–339. doi: 10.1159/000248311 PubMedCrossRefGoogle Scholar
  14. 14.
    Klein U, Klein M, Sturm H, Rothenbuhler M, Huber R, Stucki P, Gikalov I, Keller M, Hoigne R (1976) The frequency of adverse drug reactions as dependent upon age, sex and duration of hospitalization. Int J Clin Pharmacol Biopharm 13(3):187–195PubMedGoogle Scholar
  15. 15.
    Henz S, Maeder MT, Huber S, Schmid M, Loher M, Fehr T (2008) Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrol Dial Transplant 23(12):3939–3945. doi: 10.1093/ndt/gfn380 PubMedCrossRefGoogle Scholar
  16. 16.
    Johnson ES, Weinstein JR, Thorp ML, Platt RW, Petrik AF, Yang X, Anderson S, Smith DH (2010) Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiol Drug Saf 19(3):266–272. doi: 10.1002/pds.1923 PubMedCrossRefGoogle Scholar
  17. 17.
    Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351(6):543–551. doi: 10.1056/NEJMoa040135 PubMedCrossRefGoogle Scholar
  18. 18.
    Muzzarelli S, Maeder MT, Toggweiler S, Rickli H, Nietlispach F, Julius B, Burkard T, Pfisterer ME, Brunner-La Rocca HP (2012) Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy. Am J Cardiol 109(5):693–698. doi: 10.1016/j.amjcard.2011.10.027 PubMedCrossRefGoogle Scholar
  19. 19.
    Raebel MA, Ross C, Xu S, Roblin DW, Cheetham C, Blanchette CM, Saylor G, Smith DH (2010) Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med 25(4):326–333. doi: 10.1007/s11606-009-1228-x PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Hansten PD, Horn JR, Hazlet TK (2001) ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc (Wash) 41(2):161–165Google Scholar
  21. 21.
    Ho JM, Juurlink DN, Cavalcanti RB (2010) Hypokalemia following polyethylene glycol-based bowel preparation for colonoscopy in older hospitalized patients with significant comorbidities. Ann Pharmacother 44(3):466–470. doi: 10.1345/aph.1M341 PubMedCrossRefGoogle Scholar
  22. 22.
    Bonini P, Ceriotti F, Keller F, Brauer P, Stolz H, Pascual C, Garcia Beltran L, Vonderschmitt DJ, Pei P (1992) Multicentre evaluation of the Boehringer Mannheim/Hitachi 747 analysis system. Eur J Clin Chem Clin Biochem 30(12):881–899PubMedGoogle Scholar
  23. 23.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41PubMedCrossRefGoogle Scholar
  24. 24.
    K/DOQI (2002) Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39[2 Suppl 1]:S1–S266Google Scholar
  25. 25.
    Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat Theory Appl 6:65–70Google Scholar
  26. 26.
    Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustratied in the case of the binomial. Biometrika 26(4):404–413. doi: 10.1093/biomet/26.4.404 CrossRefGoogle Scholar
  27. 27.
    Indermitte J, Burkolter S, Drewe J, Krahenbuhl S, Hersberger KE (2007) Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients. Drug Saf 30(1):71–80PubMedCrossRefGoogle Scholar
  28. 28.
    Ponce SP, Jennings AE, Madias NE, Harrington JT (1985) Drug-induced hyperkalemia. Medicine (Baltimore) 64(6):357–370CrossRefGoogle Scholar
  29. 29.
    Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB (2004) Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 44(2):136–141CrossRefGoogle Scholar
  30. 30.
    Wang LM, Wong M, Lightwood JM, Cheng CM (2010) Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother 44(1):28–34. doi: 10.1345/aph.1M475 PubMedCrossRefGoogle Scholar
  31. 31.
    Uribarri J, Oh MS, Carroll HJ (1990) Hyperkalemia in diabetes mellitus. J Diabet Complications 4(1):3–7PubMedCrossRefGoogle Scholar
  32. 32.
    Schuurmans MM, Tini GM, Zuercher A, Hofer M, Benden C, Boehler A (2012) Practical approach to emergencies in lung transplant recipients: how we do it. Respiration 84(2):163–175. doi: 10.1159/000339345 PubMedCrossRefGoogle Scholar
  33. 33.
    Knoop C, Rondelet B, Dumonceaux M, Estenne M (2010) Medical complications of lung transplantation. Rev Pneumol Clin 67(1):28–49. doi: 10.1016/j.pneumo.2010.08.002 PubMedCrossRefGoogle Scholar
  34. 34.
    Ramirez E, Rossignoli T, Campos AJ, Munoz R, Zegarra C, Tong H, Medrano N, Borobia AM, Carcas AJ, Frias J (2012) Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals. Eur J Clin Pharmacol 69(1):97–110. doi: 10.1007/s00228-012-1303-9 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Emmanuel Eschmann
    • 1
    Email author
  • Patrick E. Beeler
    • 1
  • Vladimir Kaplan
    • 2
  • Markus Schneemann
    • 3
  • Gregor Zünd
    • 4
  • Jürg Blaser
    • 1
  1. 1.Research Centre for Medical Informatics, Directorate of Research and EducationUniversity Hospital ZurichZurichSwitzerland
  2. 2.Division of Internal MedicineKreisspital für das Freiamt MuriMuriSwitzerland
  3. 3.Division of Internal MedicineUniversity Hospital ZurichZurichSwitzerland
  4. 4.Directorate of Research and EducationUniversity Hospital ZurichZurichSwitzerland

Personalised recommendations